Why candida sepsis should matter to ICU physicians

Critical Care Clinics

Volumn 29, Issue 4, 2013, Pages 853-864

  Skrobik, Yoanna ^a,b   Laverdiere, Michel ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Respiratory Health Network of the FRQS   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Candidemia; Critical care; Intensive care; Invasive candidiasis; Sepsis

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

CANDIDA; CANDIDEMIA; CAREGIVER; CAREGIVER BURDEN; CRITICALLY ILL PATIENT; DISEASE COURSE; INTENSIVE CARE; INTENSIVE CARE UNIT; MEDICAL EDUCATION; PHYSICIAN; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK;

CANDIDEMIA; CRITICAL CARE; INTENSIVE CARE; INVASIVE CANDIDIASIS; SEPSIS;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; DRUG INTERACTIONS; FENTANYL; HUMANS; INFECTION CONTROL; INTENSIVE CARE UNITS; MIDAZOLAM; RISK FACTORS;

EID: 84884983371     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2013.06.007     Document Type: Review

References (57)

1. Leroy O., Gangneux J.P., Montravers P., et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009, 37(5):1612-1618.
2. Ostrosky-Zeichner L., Pappas P.G. Invasive candidiasis in the intensive care unit. Crit Care Med 2006, 34(3):857-863.
3. Marchetti O., Bille J., Fluckiger U., et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004, 38(3):311-320.
4. Eggimann P., Garbino J., Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003, 3(11):685-702.
5. Labbe A.C., Pepin J., Patino C., et al. Asingle-centre 10-year experience with Candida bloodstream infections. Can J Infect Dis Med Microbiol 2009, 20(2):45-50.
6. Garey K.W., Rege M., Pai M.P., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43(1):25-31.
7. Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49(9):3640-3645.
8. Kollef M., Micek S., Hampton N., et al. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 2012, 54(12):1739-1746.
9. Kumar A., Ellis P., Arabi Y., et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009, 136(5):1237-1248.
10. Ostrosky-Zeichner L. New approaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis 2003, 16(6):533-537.
11. Bow E.J., Evans G., Fuller J., et al. Canadian clinical practice guidelines for invasive candidiasis in adults. Can J Infect Dis Med Microbiol 2010, 21(4):e122-e150.
12. De Pauw B., Walsh T.J., Donnelly J.P., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46(12):1813-1821.
13. Nguyen M.H., Wissel M.C., Shields R.K., et al. Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis 2012, 54(9):1240-1248.
14. Pelz R.K., Lipsett P.A., Swoboda S.M., et al. The diagnostic value of fungal surveillance cultures in critically ill patients. Surg Infect (Larchmt) 2000, 1(4):273-281.
15. Eggimann P., Garbino J., Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003, 3(12):772-785.
16. Delisle M.S., Williamson D.R., Albert M., et al. Impact of Candida species on clinical outcomes in patients with suspected ventilator-associated pneumonia. Can Respir J 2011, 18(3):131-136.
17. Available at:. http://www.zapthevap.com/index.php?option=com_content%26task=view%26id=89%26Itemid=62.
18. Leon C., Ruiz-Santana S., Saavedra P., et al. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009, 37(5):1624-1633.
19. Dupont H., Bourichon A., Paugam-Burtz C., et al. Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis?. Crit Care Med 2003, 31(3):752-757.
20. Ostrosky-Zeichner L., Sable C., Sobel J., et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007, 26(4):271-276.
21. Garnacho-Montero J., Diaz-Martin A., Garcia-Cabrera E., et al. Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections. JAntimicrob Chemother 2013, 68(1):206-213.
22. Labelle A.J., Micek S.T., Roubinian N., et al. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008, 36(11):2967-2972.
23. Dupont H., Paugam-Burtz C., Muller-Serieys C., et al. Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients. Arch Surg 2002, 137(12):1341-1346. [discussion: 1347].
24. Montravers P., Dupont H., Gauzit R., et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006, 34(3):646-652.
25. Charles P.E., Doise J.M., Quenot J.P., et al. Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med 2003, 29(12):2162-2169.
26. Playford E.G., Lipman J., Sorrell T.C. Prophylaxis, empirical and preemptive treatment of invasive candidiasis. Curr Opin Crit Care 2010, 16(5):470-474.
27. Schuster M.G., Edwards J.E., Sobel J.D., et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008, 149:83-90.
28. Piarroux R., Grenouillet F., Balvay P., et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004, 32(12):2443-2449.
29. Azoulay E., Dupont H., Tabah A., et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection. Crit Care Med 2012, 40(3):813-822.
30. Group, A.K.a.t.C.D.R., The High Mortality of Candida Septic Shock is Explained by Excessive Delays in Initiation of Antifungal Therapy. ICAAC 2007, K-2174, 2007.
31. Kotwal A., Biswas D., Sharma J.P., et al. An observational study on the epidemiological and mycological profile of Candidemia in ICU patients. Med Sci Monit 2011, 17(11):CR663-CR668.
32. Cleveland A.A., Farley M.M., Harrison L.H., et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 2012, 55(10):1352-1361.
33. Garnacho-Montero J., Diaz-Martin A., Garcia-Cabrera E., et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 2010, 54(8):3149-3154.
34. Pfaller M.A., Messer S.A., Moet G.J., et al. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents 2011, 38(1):65-69.
35. Diekema D.J., Messer S.A., Brueggemann A., et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. JClin Microbiol 2002, 40:1298-1302.
36. Kett D.H., Shorr A.F., Reboli A.C., et al. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Crit Care 2011, 15(5):R253.
37. Chen L., Qin S., Xie J., et al. Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics 2008, 9(6):691-702.
38. Kimura M., Ieiri I., Mamiya K., et al. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 1998, 20(3):243-247.
39. Scholz I., Oberwittler H., Riedel K.D., et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009, 68(6):906-915.
40. Trifilio S.M., Yarnold P.R., Scheetz M.H., et al. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother 2009, 53(5):1793-1796.
41. Mikus G., Scholz I.M., Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 2011, 12(6):861-872.
42. Abele-Horn M., Kopp A., Sternberg U., et al. Arandomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 1996, 24(6):426-432.
43. Mehta S., Burry L., Fischer S., et al. Canadian survey of the use of sedatives, analgesics, and neuromuscular blocking agents in critically ill patients. Crit Care Med 2006, 34(2):374-380.
44. Feierman D.E., Lasker J.M. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metab Dispos 1996, 24(9):932-939.
45. Gorski J.C., Hall S.D., Jones D.R., et al. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994, 47(9):1643-1653.
46. Saari T.I., Laine K., Neuvonen M., et al. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Pharmacol 2008, 64(1):25-30.
47. Greenblatt D.J., Abernethy D.R., Locniskar A., et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984, 61(1):27-35.
48. Hamaoka N., Oda Y., Hase I., et al. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an invivo and invitro study. Clin Pharmacol Ther 1999, 66(2):110-117.
49. McKillop D., Wild M.J., Butters C.J., et al. Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica 1998, 28(9):845-853.
50. Albrecht S., Ihmsen H., Hering W., et al. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 1999, 65(6):630-639.
51. Malacrida R., Fritz M.E., Suter P.M., et al. Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care unit patients. Crit Care Med 1992, 20:1123-1126.
52. Dresser G.K. Coordinate induction of both cytochrome P4503A and MDR1 by StJohn's wort in healthy subjects. Clin Pharmacol Ther 2003, 73:41-50.
53. Ovakim D., Bosma K.J., Young G.B. Effect of critical illness on the pharmacokinetics and dose-response relationship of midazolam. Crit Care Med 2012, 16(Suppl 1):330.
54. de Wildt S.N., de Hoog M., Vinks A.A., et al. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. Crit Care Med 2003, 31(7):1952-1958.
55. Shehabi Y., Bellomo R., Reade M.C., et al. Early intensive care sedation predicts long-term mortality in ventilated critically ill patients. Am J Respir Crit Care Med 2012, 186(8):724-731.
56. Skrobik Y., Leger C., Cossette M., et al. Factors predisposing to coma and delirium: fentanyl and midazolam exposure, CYP3A5, ABCB1 and ABCG2 genetic polymorphisms, and inflammatory factors. Crit Care Med 2013, 41(4):999-1008.
57. Zakrzewski-Jakubiak H., Doan J., Lamoureux P., et al. Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software. Am J Geriatr Pharmacother 2011, 9(6):461-470.